Skip to content

Predictive biomarkers for inflammatory bowel disease-associated dysplasia

Predictive biomarkers for inflammatory bowel disease-associated dysplasia - Dysplasia-IBD

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51848
Enrollment
2000
Registered
2022-09-19
Start date
2023-01-03
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Dysplasia

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All adult patients (>=18 y/o) with a diagnosis of IBD undergoing surveillance colonoscopies can be enrolled after giving written informed consent to enrollment.

Exclusion criteria

Exclusion criteria: - Ongoing malignancy (other than CRC).

Design outcomes

Primary

MeasureTime frame
Identification of mucosal immune populations and the microbiome in biopsies taken from patients with aIBD with and without dysplasia, and with and without colitis-associated cancer.

Secondary

MeasureTime frame
Determination of patients* genotype (including whole genome methylome and transcriptome) associated with mucosal immunotype and microbiome in relationship to the presence of dysplasia/cancer. Determination of luminal microbiome (in biopsies and faeces) associated with mucosal immunotype and microbiome in relationship to the presence of dysplasia/cancer Determination of serum cytokines and chemokines associated with mucosal immunotype and microbiome in relationship to the presence of dysplasia/cancer

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)